Unique feature of bioSens-All™ technology enables discovery of therapeutics for pathologies linked to GPCR mistrafficking
Unique feature of bioSens-All™ technology enables discovery of therapeutics for pathologies linked to GPCR mistrafficking
Strasbourg, France, February 4, 2020 – Domain Therapeutics, a biopharmaceutical company specialized in the discovery and development of new drug candidates targeting G Protein-Coupled Receptors (GPCR) in neurology, oncology and rare diseases, today announces that it has been granted a patent in the US and in Europe covering a novel family of biosensors.
The patent, entitled ‘Biosensors for monitoring biomolecule localization and trafficking in cells’, was initially filed by Prof. Michel Bouvier and his team and is part of the technology licensed to Domain Therapeutics by the Universities of Montreal and McGill, Canada.
The trafficking biosensors covered by the patent are used by Domain Therapeutics to monitor the intracellular trafficking and recycling of GPCRs. They belong to a new generation of sensors and complete the panel of 63 unique biosensors constituting the bioSens-All™ technology. These biosensors are designed to profile G Proteins, including G12 and G13, Beta-arrestins, second messengers and receptor trafficking.
“This granted patent illustrates our strategy to stay at the forefront of innovation in technologies for challenging GPCRs. It will help the company address unmet medical needs with drugs acting through brand new mechanisms of action,” said Pascal Neuville, CEO, Domain Therapeutics. “In collaboration with Prof. Michel Bouvier, we have already taken advantage of this unique technology to launch a chaperone program targeting a mutated GPCR with impaired trafficking.”
About G Protein-Coupled Receptors
GPCRs belong to the family of membrane receptors and constitute one of the main classes of therapeutic targets for many indications. The binding of a hormone or a specific ligand to a receptor’s binding site activates one or several pathways for intracellular signaling. This enables the cell to provide an adapted response to the change in its environment. The drugs that target GPCRs represent about 30% of all treatments on the market, but only address 28% of the GPCRs. Thus, GPCRs remain largely underexploited to date. Domain Therapeutics proposes novel drug candidates for the remaining 70%, thanks to its unique drug discovery engine using technologies such as bioSens-All™.
About Domain Therapeutics
Domain Therapeutics is a biopharmaceutical company dedicated to the discovery and development of new drug candidates targeting transmembrane receptors, in particular, G Protein-Coupled Receptors (GPCRs), one of the most important classes of drug targets. Domain identifies and develops candidates (allosteric modulators and biased ligands) through its innovative approach and technologies. Domain enters into collaboration with pharma companies for the discovery of new treatments and creates asset-centric vehicles for the development of its internal pipeline of drug candidates for central nervous system disorders, cancer and rare diseases. These asset-centric companies attract investment for development up to clinical proof-of-concept and exit is through a trade sale.
www.domaintherapeutics.com
